Skip to main content

Are you a legal professional? Visit our professional site

Please enter a legal issue and/or a location
Begin typing to search, use arrow keys to navigate, use enter to select

FDA Seeks Halt of Cymbalta Promotion

By Admin on October 03, 2007 12:12 PM

The U.S. Food and Drug Administration (FDA) has determined that a professional mailer on Cymbalta from manufacturer Eli Lilly and Co. is "false and misleading" in that it "overstates the efficacy of Cymbalta and omits some of the most serious and important risk information associated with its use" in violation of federal law. FDA has ordered Lilly to cease dissemination of these promotional materials. Cymbalta has been approved for treatment of major depressive disorder, management of pain associated with diabetes, and treatment of generalized anxiety disorder.

You Don’t Have To Solve This on Your Own – Get a Lawyer’s Help

Meeting with a lawyer can help you understand your options and how to best protect your rights. Visit our attorney directory to find a lawyer near you who can help.

Or contact an attorney near you:
Copied to clipboard

Find a Lawyer

More Options